Inovio Pharmaceuticals (INO) vs Unicycive Therapeutics (UNCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Unicycive Therapeutics (UNCY) has outperformed Inovio Pharmaceuticals (INO) over the past year, losing 14.7% versus a loss of 57.4%. Over five years, UNCY leads with a -85.1% price change compared with -98.7% for INO. Inovio Pharmaceuticals is the larger company by market cap ($118.9 million vs $112.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INO | UNCY |
|---|---|---|
| Share price | $1.15 | $4.11 |
| Market cap | $118.91M | $112.59M |
| 1-day change | +5.50% | +0.98% |
| YTD return | -37.36% | -29.46% |
| 1-year return | -57.42% | -14.68% |
| 5-year return | -98.71% | -85.06% |
| Forward P/E | — | 2.44 |
| EPS (TTM) | $-0.90 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.72 | $8.74 |
| 52-week low | $0.56 | $3.93 |
| Distance from 52-week high | -57.72% | -52.97% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +175.65% | +591.00% |
| Average volume | 3.86M | 839.29K |
| Shares outstanding | 103.40M | 27.39M |
| Employees | 112 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- UNCY has outperformed INO by 42.7 percentage points over the past year.
About Inovio Pharmaceuticals
INO stock →Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees
About Unicycive Therapeutics
UNCY stock →Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
INO vs UNCY FAQ
Which is bigger, Inovio Pharmaceuticals or Unicycive Therapeutics?
Inovio Pharmaceuticals (INO) is larger, with a market capitalization of $118.91M compared with $112.59M for Unicycive Therapeutics (UNCY).
Which stock has performed better over the past year, INO or UNCY?
UNCY returned -14.68% over the past 12 months, compared with -57.42% for INO (price return, excluding dividends). Past performance does not predict future results.
Are Inovio Pharmaceuticals and Unicycive Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.